New Oral Antiandrogens Gain Prominence in Prostate Cancer Treatment Market, According to MP Advisors Report Available at MarketPublishers.com
09 Feb 2017 • by Natalie Aster
LONDON – With an upsurge in prevalence rates of prostate cancer and availability of new treatment modalities like Xtandi, Zytiga, Xofigo and Cabazitaxel in past several years, the market has seen the extension of the role of newer oral antiandrogens to treat patients with metastatic castration-resistant prostate cancer (CRPC) where a high level of unmet need was identified. Thus, the WW market size of prostate cancer drugs increased from USD 2.5 billion in 2011 to USD 7 billion as of 2016. Now non-metastatic CRPC, Xtandi/Zytiga and HSPC resistance population are the markets where in novel drugs are under clinical development.
Close to 8 plus prostate cancer drugs are in phase III development and 26 plus drug products are in phase II trials – success of a few (ODM-201, ARN-509, GX301, AZD 5363) in the offing is predicted to expand the nmCRPC, mHSPC market and Xtandi/Zytiga resistant population market by 2023-end. Longer treatment duration and high rates of prevalence make earlier setting marketplace more appealing and bigger for novel options than the late stage in case they succeed.
Additionally, 6 therapeutic vaccines are currently in development to treat prostate cancer. Novel PD-L1 IO therapy has brought more hope of treating cancer in a safer way.
New report “Prostate Cancer - Newer Antiandrogens & Emerging Therapies Targeting a “Watchful Waiting” and Resistance Population” prepared by MP Advisors provides a comprehensive analysis of the prostate cancer treatment market landscape focusing on the pertinent drugs in development in the pharma universe.
The study gives details about present-day unmet need, changing regulations, reimbursement issues as well as market dynamics of the drugs used to treat prostate cancer. The report sheds light on pipeline antiandrogens, prostate cancer drug products in late stages of development and new MOA; it also identifies and examines the leading companies engaged in the development of prostate cancer drugs. The research also gives insights into clinical trial strategy of combination drugs in pipeline and/or already marketed, as well as canvasses the competitive landscape within this therapeutic area to discover treatment paradigm fit and market potential of novel drugs to treat the carcinoma of the prostate.
More comprehensive research reports by the publisher can be found at MP Advisors page.